Mirae Asset Global Investments
KPTI icon

Mirae Asset Global Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Mirae Asset Global Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,493
Closed -$145K – 2653
2023
Q1 		$145K Buy
+2,493
New +$123K ﹤0.01% 2389
2022
Q4 		– Sell
-2,146
Closed -$176K – 2565
2022
Q3 		$176K Buy
2,146
+643
+43% +$48K ﹤0.01% 2383
2022
Q2 		$102K Buy
+1,503
New +$138K ﹤0.01% 2303

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Mirae Asset Global Investments's KPTI Position: Q2 2023 in Review

Mirae Asset Global Investments sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 2,493 shares — an estimated $145K sold.

Mirae Asset Global Investments first reported a position in KPTI in Q2 2022 and held it in 3 quarters. The position peaked at $176K in Q3 2022. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

  • Mirae Asset Global Investments reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Mirae Asset Global Investments sold 2,493 Karyopharm Therapeutics shares in Q2 2023, an estimated $145K.
  • Mirae Asset Global Investments first reported a position in Karyopharm Therapeutics in Q2 2022 and held it in 3 quarters.
  • Mirae Asset Global Investments's Karyopharm Therapeutics position peaked at $176K in Q3 2022.
  • 137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Mirae Asset Global Investments's 13F filing for Q2 2023, filed 10 Aug 2023.